LabCorp® Scheduled to Present at Thomas Weisel Healthcare Conference

Burlington, NC, April 3, 2001 -- Laboratory Corporation of America® Holdings (LabCorp® ) (NYSE: LH) today announced that Bradford T. Smith, executive vice president of public affairs, is scheduled to speak at the Thomas Weisel Healthcare Conference in San Francisco on April 3. The presentation will be audio-webcast live at 2:00 p.m. Pacific Standard Time/ 5:00 p.m. Eastern Standard Time, with a rebroadcast available for 30 days, and may be heard online at www.labcorp.com.

At the conference, Mr. Smith will reiterate Company guidance for 2001, as filed in an 8K on February 14, 2001. Mr. Smith will state, "We expect revenue growth of 10 percent to 11 percent, with a bad debt rate of 9.7 percent of sales, EBITDA margins of approximately 20.5 percent to 21 percent of sales, and EPS growth of approximately 45 percent to 50 percent."

The first clinical laboratory to fully embrace genomic testing, Laboratory Corporation of America® Holdings (LabCorp® ) has been a pioneer in commercializing new diagnostic technologies. As a national laboratory with annual revenues of $1.9 billion in 2000 and over 18,000 employees, the company offers more than 4,000 clinical tests ranging from simple blood analyses to sophisticated molecular diagnostics. Serving over 200,000 clients nationwide, LabCorp leverages its expertise in innovative clinical testing technology with its Centers of Excellence. The Center for Molecular Biology and Pathology, in Research Triangle Park (RTP), North Carolina, develops applications for polymerase chain reaction (PCR) technology. LabCorp's National Genetics Institute in Los Angeles is an industry leader in developing novel, highly sensitive PCR methods for testing hepatitis C and other infectious agents, and its Center for Esoteric Testing in Burlington, North Carolina, performs the largest volume of specialty testing in the network. LabCorp's clients include physicians, state and federal government, managed care organizations, hospitals, clinics, pharmaceutical and Fortune 1000 companies, and other clinical laboratories.

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2000 and subsequent SEC filings.